PER-1- and OXA-10-like β-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates from intensive care unit patients in Istanbul, Turkey

Clinical Microbiology and Infection

Volumn 11, Issue 3, 2005, Pages 193-198

  Aktaş, Zerrin ^a   Poirel, L ^b   Salcioglu M ^a   Ozcan P E ^a   Midilli, K ^c   Bal, C ^a   Ang O ^a   Nordmann, P ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b BICÊTRE HOSPITAL   (France)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Ceftazidime resistance; Intensive care unit; OXA 10; PER 1; Pseudomonas aeruginosa; lactamase

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAMASE; CEFEPIME; CEFOPERAZONE; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN OXA 10; PROTEIN PER 1; SULTAMICILLIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA SEQUENCE; GENE IDENTIFICATION; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOM AMPLIFIED POLYMORPHIC DNA; SEQUENCE ANALYSIS; TURKEY (REPUBLIC);

PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 14844347833     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.01067.x     Document Type: Article

References (41)

1. Pechere JC, Köhler T. Patterns and modes of β-lactam resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 1999; 5: 15-18.
2. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47: 247-250.
3. Weldhagen GF, Poirel L, Nordmann P. Ambler Class A extended spectrum β-lactamases in Pseudomonas aeruginosa. Novel developments and clinical impact. Antimicrob Agents Chemother 2003; 47: 2385-2392.
4. Nordmann P, Guibert M. Extended-spectrum β-lactamases in Pseudomonas aeruginosa. J Antimicrob Chemother 1998; 42: 128-131.
5. Naas T, Poirel L, Karim A, Nordmann P. Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum β-lactamase VEB-1 in Pseudomonas aeruginosa. FEMS Microbiol Lett 1999; 176: 411-419.
6. Marchandin H, Jean-Pierre A, De Champs C et al. Production of TEM-24 plasmid-mediated extended-spectrum beta-lactamase by a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 213-216.
7. Poirel L, Ronco E, Naas T, Nordmann P. Extended-spectrum β-lactamase TEM-4 in Pseudomonas aeruginosa. Clin Microbiol Infect 1999; 5: 651-652.
8. Nordmann P, Ronco E, Naas T, Duport C, Michel-Briand Y, Labia R. Characterization of a novel β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 962-969.
9. Vahaboglu H, Ozturk R, Aygun G et al. Widespread detection of PER-1 type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41: 2265-2269.
10. Vahabboǧlu H, Saribaş S, Akbal H, Ozturk R, Yücel A. Activities of cefepime and five other antibiotics against nosocomial PER-1 type and/or OXA-10-type β-lactamase producing Pseudomonas aeruginosa and Acinetobacter spp. J Antimicrob Chemother 1998; 42: 269-270.
11. Danel F, Hall LMC, Gur D, Akalin HE, Livermore DM. β-lactamase in Pseudomonas aeruginosa. J Antimicrob Chemother 1995; 35: 281-294.
12. Naas T, Nordmann P. OXA-type β-lactamases. Curr Pharm Design 1999; 5: 865-879.
13. Danel F, Lucinda M, Hall MC, Gur D, Livermore DM. OXA-15, an extended-spectrum variant of OXA-2 β-lactamase, isolated from Pseudomonas aeruginosa strain. Antimicrob Agents Chemother 1997; 41: 785-790.
14. Danel F, Hall LMC, Duke B, Gur D, Livermore DM. OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 1362-1366.
15. Hall LMC, Livermore DM, Gur D, Akova M, Akalin HE. β-Lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 1637-1644.
16. Poirel L, Gerome P, Champs CD, Stephanazzi J, Naas T, Nordmann P. Integron-located OXA-32 gene cassette encoding an extended-spectrum variant of OXA-2 β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 566-569.
17. Poirel L, Girlich D, Naas T, Nordmann P. OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob Agents Chemother 2001; 45: 447-453.
18. Mugnier P, Casin I, Bouthors AT, Collatz E. Novel OXA-10 derived extended-spectrum β-lactamases selected in vivo or in vitro. Antimicrob Agents Chemother 1998; 42: 3113-3116.
19. Philippon L, Naas T, Bouthors AT, Barakett V, Nordmann P. OXA-18, a class D clavulanic acid-inhibited extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41: 2188-2195.
20. Albert S, Kirchner J, Thomas H, Behne M, Schur J, Brade D. Role of quantitative cultures and microscopic examinations of endotracheal aspirates in the diagnosis of pulmonary infections in ventilated patients. J Hosp Infect 1997; 37: 25-37.
21. Working Party of the British Society for Antimicrobial Chemotherapy. A guide to sensitivity testing. J Antimicrobial Chemotherapy 1991; 27(suppl D): 1-50.
22. Nordmann P, Naas T. Sequence analysis of PER-1 extended-spectrum β-lactamase from Pseudomonas aeruginosa and comparison with Class A β-lactamases. Antimicrob Agents Chemother 1994; 38: 104-114.
23. Huovinen P, Huovinen S, Jacoby GA. Sequence of PSE-2 β-lactamase. Antimicrob Agents Chemother 1988; 32: 134-136.
24. Luzzaro F, Mantengoli E, Perilli M et al. Dynamics of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase. J Clin Microbiol 2001; 39: 1865-1870.
25. Vahaboǧlu H, Dodanli S, Eroǧlu C et al. Characterization of multiple-antibiotic-resistant Salmonella typhimurium strains: molecular epidemiology of PER-1 producing isolates and evidence for nosocomial plasmid exchange by a clone. J Clin Microbiol 1996; 34: 2942-2946.
26. Vahaboǧlu H, Hall LMC, Mulazimoǧlu L, Dodanli S, Yildirim I, Livermore D. Resistance to extended-spectrum cephalosporins caused by PER-1 β-lactamase, in Salmonella typhimurium from Istanbul. J Med Microbiol 1995; 43: 294-299.
27. Bahar UG, Gulay Z, Mert A. PER-1 ESBL production in a urinary isolate of Providencia rettgeri. Clin Microbiol Infect 2003; 9 suppl 1): 306.
28. Paterson DL, Hujer KM, Hujer AM et al. Extended-spectrum β-lactamases in Klebsiella pneumoniae blood-stream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrob Agents Chemother 2003; 47: 3554-3560.
29. Vahaboglu H, Ozturk R, Akbal H, Saribas S, Tansel O, Coskunkan F. Practical approach for detection and identification of OXA-10 derived ceftazidime-hydrolyzing extended-spectrum β-lactamases. J Clin Microbiol 1998; 36: 827-829.
30. Poirel K, Karim A, Mercat A et al. Extended-spectrum β-lactamase producing strain of Acinetobacter baumannii isolated from a patient in France. J Antimicrob Chemother 1999; 43: 157-158.
31. Claeys G, Verschraegen G, Baere T, Vaneechoutte M. PER-1 β-lactamase-producing Pseudomonas aeruginosa in an intensive care unit. J Antimicrob Chemother 2000; 45: 924-925.
32. Yong D, Shin JH, Kim S et al. High prevalence of PER-1 extended spectrum beta lactamase producing Acinetobacter baumannii in Korea. Antimicrob Agents Chemother 2003; 47: 1749-1751.
33. De Champs C, Poirel L, Bonnet R et al. Prospective survey of β-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 2002; 46: 3031-3034.
34. Pagani L, Mighavacca R, Pallecchi L et al. Emerging extended-spectrum β-lactamases in Proteus mirabilis. J Clin Microbiol 2002; 40: 1549-1552.
35. Pereira M, Perilli M, Mantengoli E et al. PER-1 extended-spectrum beta-lactamase production in an Alcaligenes faecalis clinical isolate resistant to expanded-spectrum cephalosporins and monobactams from a hospital in northern Italy. Microb Drug Resist 2000; 6: 85-90.
36. Docquier JD, Luzzaro F, Amicosante G, Toniolo A, Rossolini GM. Multidrug-resistant Pseudomonas aeruginosa producing PER-1 extended-spectrum serine β-lactamase and VIM-2 metallo-β-lactamase. Emerg Infect Dis 2001; 7: 910-911.
37. Günseren F, Mamikoǧlu L, Öztürk S et al. A surveillance study of antimicrobial resistance of Gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey. J Antimicrob Chemother 1999; 43: 373-378.
38. Gencer S, Ak O, Benzonana N, Batirel A, Ozer S. Susceptibility patterns and cross resistances of antibiotics against Pseudomonas aeruginosa in a teaching hospital of Turkey. Ann Clin Microbiol Antimicrob 2002; 1: 2-5.
39. Gonlugur U, Bakici MZ, Ozdemir L, Akkurt I, Icagasioglu S, Gultekin F. Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish university hospital. Ann Clin Microbiol Antimicrob 2003; 2: 5-8.
40. Pirnay JP, De Vos D, Cochez C et al. Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistance of a multidrug-resistant clone and a silver sulfadiazine-resistant clone. J Clin Microbiol 2003; 41: 1192-1102.
41. Bergmans DCJ, Bonten JM, Tiel FH et al. Cross-colonisation with Pseudomonas aeruginosa of patients in an intensive care unit. Thorax 1998; 53: 1053-1058.